Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation

American Journal of Hematology

Volumn 82, Issue 1, 2007, Pages 1-5

  Yang, Deok Hwan ^a   Lee, Je Jung ^a   Mun, Yeung Chul ^b   Shin, Ho Jin ^c   Kim, Yeo Kyeoung ^a   Cho, Sang Hee ^a   Chung, Ik Joo ^a   Seong, Chu Myong ^b   Kim, Hyeoung Joon ^a  

^a Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^b Ewha Womans University   (South Korea)

^c Pusan National University Hospital   (South Korea)

Author keywords

Allogeneic stem cell transplantation; AML with t(8; 21); CD56 expression; Disease free survival; Prognostic significance; Survival

Indexed keywords

CD56 ANTIGEN; CYTARABINE; ENOCITABINE; IDARUBICIN; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION 8; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME;

ADOLESCENT; ADULT; ANTIGENS, CD56; ANTIMETABOLITES, ANTINEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSLOCATION, GENETIC; TRANSPLANTATION, HOMOLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 33845931996     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20739     Document Type: Article

References (25)

1. Fenaux P, Preudhomme C, Lai JL, Morel P, Beuscart R, Bauters F. Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: A report on 283 cases. Br J Haematol 1989;73:61-67.
2. Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21) (q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 1999;17:3767-3775.
3. Schiffer CA, Lee EJ, Tomiyasu T, Wiernik PH, Testa JR. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 1989;73:263-270.
4. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998;58:4173-4179.
5. Ferrara F, Morabito F, Martino B, et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol 2000;18:1295-1300.
6. Raspadori D, Damiani D, Lenoci M, et al. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia 2001;15:1161-1164.
7. Graf M, Reif S, Hecht K, et al. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML). Ann Hematol 2005;84: 287-297.
8. Di Bona E, Sartori R, Zambello R, Guercini N, Madeo D, Rodeghiero F. Prognostic significance of CD56 antigen expression in acute myeloid leukemia. Haematologica 2002;87:250-256.
9. Munoz L, Nomdedeu JF, Brunei S, Villamor N, Tormo M, Sierra J. CD56 expression could be associated with monocytic differentiation in acute myeloid leukemia with t(8;21). Haematologica 2001;86:763-764.
10. Byrd JC, Edenfield WJ, Shields DJ, Dawson NA. Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: A clinical review. J Clin Oncol 1995;13:1800-1816.
11. Byrd JC, Weiss RB, Arthur DC, et al. Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): Results from Cancer and Leukemia Group B 8461. J Clin Oncol 1997;15:466-475.
12. Chang H, Brandwein J, Yi QL, Chun K, Patterson B, Brien B. Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. Leuk Res 2004;28:1007-1011.
13. Schaich M, Koch R, Soucek S, Repp R, Ehninger G, Illmer T. A sensitive model for prediction of relapse in adult acute myeloid leukaemia with t(8;21) using white blood cell count, CD56 and MDR1 gene expression at diagnosis. Br J Haematol 2004;125:477-479.
14. Schaich M, Ritter M, Illmer T, et al. Mutations in ras protooncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia. Br J Haematol 2001;112:300-307.
15. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620-625.
16. Lee JJ, Chung IJ, Yang DH, et al. Clinical significance of CD56 expression in patients with acute myeloid leukemia. Leuk Lymphoma 2002;43:1897-1899.
17. Park HS, Kim DW, Kim CC, et al. Induction chemotherapy with idarubicin plus N4-behenoyl-1-β-D-arabinofuranosylcytosine in acute myelogenous leukemia: A newly designed induction regimen-A prospective, cooperative multicenter study. Semin Hematol 1996;33(4 Suppl 3):24-29.
18. Baer MR, Stewart CC, Lawrence D, et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 1997;90:1643-1648.
19. Kita K, Nakase K, Miwa H, et al. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21) (q22;q22) chromosomal abnormality: Frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood 1992;80:470-477.
20. Seymour JF, Pierce SA, Kantarjian HM, Keating MJ, Estey EH. Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). Leukemia 1994;8:823-826.
21. Schoch C, Haase D, Haferlach T, et al. Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): An additional deletion in 9q is an adverse prognostic factor. Leukemia 1996;10:1288-1295.
22. Billstrom R, Johansson B, Fioretos T, et al. Poor survival in t(8;21) (q22;q22)-associated acute myeloid leukaemia with leukocytosis. Eur J Haematol 1997;59:47-52.
23. Pancook JD, Reisfeld RA, Varki N, Vitiello A, Fox RI, Montgomery AM. Expression and regulation of the neural cell adhesion molecule L1 on human cells of myelomonocytic and lymphoid origin. J Immunol 1997; 158:4413-4421.
24. Hsiao CH, Tang JL, Yao M, et al. High incidence of CD56 expression and relapse rate in acute myeloid leukemia patients with t(8;21) in Taiwan. J Formos Med Assoc 2002;101:393-398.
25. Schaich M, Harbich-Brutscher E, Pascheberg U, et al. Association of specific cytogenetic aberrations with mdr1 gene expression in adult myeloid leukemia and its implication in treatment outcome. Haematologica 2002;87:455-464.